What gene does bosutinib target?

Bosutinib (Bosutinib) is a new second-generation tyrosine kinase inhibitor (TKI) targeting the Bcr-Abl protein. Bosutinib was formerly known as SKI-606, and both kinases are thought to be involved in the development of malignancies. Studies have shown that the Bcr-Abl domain interacts and activates Lyn and Hck Src kinases through phosphorylation and direct binding. This dual inhibition may help overcome certain types of drug resistance that often occur in advanced stages of chronic myelogenous leukemia. Due to the sequence homology and structural similarity between Src and Abl binding domains, ATP inhibitors targeting the inactive conformation of Src are also effective Abl inhibitors.